www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

USEUROPEAFRICAASIA 中文雙語(yǔ)Fran?ais
World
Home / World / Reporter's Journal

Conquering malaria remains a daunting dilemma, but there's hope

By Chris Davis | China Daily USA | Updated: 2017-04-27 11:18

The war against malaria has made progress over the past decade, but there is still a long way to go, and Chinese researchers are leading the way on more than one front.

Roughly half of the world's population - 3 billion people - still remains at risk.

In 2006, there were 266 million cases a year leading to 750,000 deaths, according to the World Health Organization.

By 2015, the numbers had diminished, but remained huge - 212 million cases, 429,000 deaths.

And a staggering 90 percent of all cases are in Africa.

Dr Deng Changsheng, manager of the department of science and technology at Guangzhou University of Chinese Medicine, told a group of 27 journalists visiting from Africa recently, that strategy used to cause a major decline in malarial regions of China is showing promise in Africa.

The approach is called fast elimination of malaria by source eradication (FEMSE). It involves mass drug administration (MDA) of artemisinin-based combination therapies (ACT) - in other words, clearing an affected population of the malarial parasites by mass drug administration.

Artemisinin, by the way, is the drug that won 85-year-old Chinese pharmacologist Tu Youyou the 2015 Nobel Prize for Medicine. She had mined the recipe, derived from the sweet wormwood plant, from the annals of ancient Chinese medicine. Today it saves hundreds of thousands of lives a year in Africa alone.

The drug has not been cheap, but Deng said the cost could be brought to as low as $15 per person over the next decade. Today it's about $40, according to Deng.

Thanks to a worldwide push, ACT treatments rose from 187 million in 2010 to 311 million in 2015.

The big fear facing the effort right now is that the parasites are showing signs of developing a resistance to artemisinin, the same way some strains of tuberculosis are shunning off some of modern medicine's most potent antibiotics.

"The spread of artemisinin resistance in Africa would be a major setback in the fight against malaria, as ACT is the only effective and widely used anti-malarial treatment at the moment," writes Professor Arnab Pain of King Abdullah University of Science and Technology in the current issue of the New England Journal of Medicine.

"Therefore it is very important to regularly monitor artemisinin resistance on a worldwide scale," he added.

The study, led by Jun Cao of the Institute for Parasitic Diseases in China, found drug-resistant malarial parasites in a Chinese patient who had been in Equatorial Guinea and returned to China. The ACT therapy, which usually takes three days to rid the patient of the disease, took five days in this case.

This "partial resistance", they said, has been noted in other parts of Southeast Asia, and the great fear is that "partial" morphs into "complete".

"This is one of the great challenges facing us in the fight against malaria," the World Health Organization says on its website.

The holy grail of that fight, of course, remains a vaccine, and The Associated Press reports that three African nations have just been chosen to test the world's first malaria vaccine.

WHO announced Monday that Ghana, Kenya and Malawi will begin piloting an injectable vaccine next year with hundreds of thousands of young children, who have been at highest risk of death.

The vaccine, which has partial effectiveness, has the potential to save tens of thousands of lives if used with existing measures, WHO's regional director for Africa, Dr Matshidiso Moeti, said in a statement. The challenge is whether impoverished countries can deliver the required four doses of the vaccine for each child.

The vaccine will be tested on children 5 to 17 months old to see whether its protective effects shown so far in clinical trials can hold up under real-life conditions. At least 120,000 children in each of the three countries will receive the vaccine, which has taken decades of work and hundreds of millions of dollars to develop.

Kenya, Ghana and Malawi were chosen for the vaccine pilot because all have strong prevention and vaccination programs but continue to have high numbers of malaria cases, WHO said. The countries will deliver the vaccine through their existing vaccination programs.

WHO is hoping to wipe out malaria by 2040, despite the increasing resistance problems to both drugs and insecticides used to kill mosquitoes.

The vaccine was developed by GlaxoSmithKline, and the $49 million for the first phase of the pilot is being funded by the global vaccine alliance GAVI, UNITAID and Global Fund to Fight AIDS, Tuberculosis and Malaria.

Contact the writer at chrisdavis@chinadailyusa.com.

 

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 国产一级片在线 | 欧美一级aa毛片禁片 | 欧美精品午夜久久久伊人 | 国产精品午夜国产小视频 | 国产综合亚洲专区在线 | 国产一区在线免费观看 | 亚洲免费区 | 最新亚洲一区二区三区四区 | 中文成人在线 | 国产午夜人做人视频羞羞 | 女人精aaaa片一级毛片女女 | 美女一级毛片免费观看 | 5x社区直接进入一区二区三区 | 久久亚洲国产成人影院 | 成年人毛片 | 日韩字幕一中文在线综合 | 99视频网站 | 成人午夜视频在线观看 | 欧美一级高清免费播放 | 手机在线观看亚洲国产精品 | 黄色免费在线观看视频 | 精品国产品欧美日产在线 | 最新精品亚洲成a人在线观看 | 成人网视频在线观看免费 | 欧美色综合高清视频在线 | 精品久久久久久久久久久久久久久 | 国产精品久久不卡日韩美女 | 日韩高清成人毛片不卡 | 国产欧美一区二区三区精品 | 玖草在线视频 | 东莞a级毛片 | 久久国产精品99久久久久久牛牛 | 日本高清视频免费在线观看 | 真正全免费视频a毛片 | 鲁丝片一区二区三区免费 | 国产精品一区二区久久精品 | 久久伊人热 | 久久久久久久久中文字幕 | 久久中文字幕免费视频 | 国产91香蕉 | 国产高清一国产免费软件 |